Arrowhead Research Corporation (ARWR) Valuation
Historical valuation analysis based on 500 data points (2024-09-23 to 2026-09-21)
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproductio...
Arrowhead Research Corporation (ARWR) currently trades at a P/E ratio of 40.10 (historical range: 38.27–50.78, median: 44.41), placing it at the 15th percentile — cheap relative to its history, P/S ratio of 15.46 (range: 2.39–1075.19, 50th percentile — near its historical average), EV/EBITDA of 25.15 (range: 23.92–32.34, 15th percentile).
Arrowhead Research Corporation appears undervalued relative to its historical range, with most valuation metrics below their median levels.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/E Ratio | 40.10 | 38.27 | 44.41 | 50.78 | 15th | cheap relative to its history |
| P/S Ratio | 15.46 | 2.39 | 15.27 | 1075.19 | 50th | near its historical average |
| EV/EBITDA | 25.15 | 23.92 | 28.05 | 32.34 | 15th | cheap relative to its history |
| FCF Yield | 0.04 | 0.00 | 0.01 | 0.04 | 92th | cheap relative to its history |
Arrowhead Research Corporation (ARWR) Valuation & P/E History
Arrowhead Research Corporation (ARWR) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry currently trading at $68.58 with a market capitalization of $9.7 billion. This page provides historical valuation analysis for ARWR based on 500 data points covering 2024-09-23 to 2026-09-21. The P/E ratio of 40.10 is below the historical median of 44.41, placing ARWR at the 15th percentile of its valuation range. The P/S ratio of 15.46 compares to a median of 15.27.
ARWR Valuation Metrics & Historical Range
The valuation table above shows Arrowhead Research Corporation's current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether ARWR is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests ARWR is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for Arrowhead Research Corporation.
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is ARWR Overvalued or Undervalued?
Arrowhead Research Corporation appears undervalued relative to its historical range, with most valuation metrics below their median levels. The overall valuation percentile of 27 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive ARWR is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full ARWR analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.ARWR trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.